• Media type: E-Article
  • Title: The cost-utility of early use of high-flow nasal cannula in bronchiolitis
  • Contributor: Buendía, Jefferson Antonio [VerfasserIn]; Acuña-Cordero, Ranniery [VerfasserIn]; Rodriguez-Martinez, Carlos E. [VerfasserIn]
  • imprint: 2021
  • Published in: Health economics review ; 11(2021), 1 vom: Dez., Artikel-ID 41, Seite 1-8
  • Language: English
  • DOI: 10.1186/s13561-021-00339-7
  • ISSN: 2191-1991
  • Identifier:
  • Keywords: Health economics ; Public health ; Healthcare ; Asthma ; Oxygen ; Cannula ; Aufsatz in Zeitschrift
  • Origination:
  • Footnote:
  • Description: Background: High-flow nasal cannula (HFNC) oxygen is a non-invasive ventilation system that was introduced as an alternative to CPAP (continuous positive airway pressure), with a marked increase in its use in pediatric care settings. This study aimed to evaluate the cost-effectiveness of early use of HFNC compared to oxygen by nasal cannula in an infant with bronchiolitis in the emergency setting. Methods: A decision tree model was used to estimate the cost-effectiveness of HFNC compared with oxygen by nasal cannula (control strategy) in an infant with bronchiolitis in the emergency setting. Cost data were obtained from a retrospective study on bronchiolitis from tertiary centers in Rionegro, Colombia, while utilities were collected from the literature. Results: The QALYs per patient calculated in the base-case model were 0.9141 (95% CI 0.913-0.915) in the HFNC and 0.9105 (95% CI 0.910-0.911) in control group. The cost per patient was US$368 (95% CI US$ 323-411) in HFNC and US$441 (95% CI US$ 384-498) per patient in the control group. Conclusions: HFNC was cost-effective HFNC compared to oxygen by nasal cannula in an infant with bronchiolitis in the emergency setting. The use of this technology in emergency settings will allow a more efficient use of resources, especially in low-resource countries with high prevalence of bronchiolitis.
  • Access State: Open Access
  • Rights information: Attribution (CC BY)